Non-opioid analgesic combinations following total hip arthroplasty (RECIPE): a randomised, placebo-controlled, blinded, multicentre trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background
Multimodal postoperative analgesia following total hip arthroplasty is recommended, but the optimal combination of drugs remains uncertain. The aim of the RECIPE trial was to investigate the relative benefit and harm of the different combinations of paracetamol, ibuprofen, and the analgesic adjuvant dexamethasone for treatment of postoperative pain following total hip arthroplasty.

Methods
The RECIPE trial was a randomised, blinded, placebo-controlled trial conducted at nine Danish hospitals. Adults scheduled for total hip arthroplasty were randomly assigned (1:1:1:1) using a computer-generated list with stratification by site to receive combinations of oral paracetamol 1000 mg every 6 h, oral ibuprofen 400 mg every 6 h, or a single-dose of intravenous dexamethasone 24 mg in the following groups: paracetamol plus ibuprofen, ibuprofen plus dexamethasone, paracetamol plus dexamethasone, and paracetamol plus ibuprofen plus dexamethasone. The primary outcome was 24 h intravenous morphine consumption, analysed in a modified intention-to-treat population, defined as all randomly assigned participants who underwent total hip arthroplasty. The predefined minimal important difference was 8 mg. Safety outcomes included serious and non-serious adverse events within 90 days and 24 h. The trial was registered with ClinicalTrials.gov, NCT04123873.

Findings
Between March 5, 2020, and Nov 15, 2022, we randomly assigned 1060 participants, of whom 1043 (589 [56%] women and 454 [44%] men) were included in the modified intention-to-treat population. 261 were assigned to paracetamol plus ibuprofen, 262 to ibuprofen plus dexamethasone, 262 to paracetamol plus dexamethasone, and 258 to paracetamol plus ibuprofen plus dexamethasone. Median 24 h morphine consumption was 24 mg (IQR 12–38) in the paracetamol plus ibuprofen group, 20 mg (12–32) in the paracetamol plus dexamethasone group, 16 mg (10–30) in the ibuprofen plus dexamethasone group, and 15 mg (8–26) in the paracetamol plus ibuprofen plus dexamethasone group. The paracetamol plus ibuprofen plus dexamethasone group had a significantly reduced 24 h morphine consumption compared with paracetamol plus ibuprofen (Hodges-Lehmann median difference –6 mg [99% CI –10 to –3]; p<0·0001) and paracetamol plus dexamethasone (–4 mg [–8 to –1]; p=0·0013), however, none of the comparisons showed differences reaching the minimal important threshold of 8 mg. 91 (35%) of 258 participants in the paracetamol plus ibuprofen plus dexamethasone group had one or more adverse events, compared with 99 (38%) of 262 in the ibuprofen plus dexamethasone group, 103 (39%) of 262 in the paracetamol plus dexamethasone group, and 165 (63%) of 261 in the paracetamol plus ibuprofen group.

Interpretation
In adults undergoing total hip arthroplasty, a combination of paracetamol, ibuprofen, and dexamethasone had the lowest morphine consumption within 24 h following surgery and the most favourable adverse event profile, with a lower incidence of serious and non-serious adverse events (primarily driven by differences in nausea, vomiting, and dizziness) compared with paracetamol plus ibuprofen.
OriginalsprogEngelsk
TidsskriftThe Lancet Rheumatology
Vol/bind6
Udgave nummer4
Sider (fra-til)e205-e215
Antal sider11
ISSN2665-9913
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
The trial was independently funded by the Novo Nordisk Foundation and Næstved-Slagelse-Ringsted Hospital's Research Fund. The Steering Committee would like to express our sincere gratitude to our collaborators. This trial could not have been conducted without major contributions from our research staff and the clinical staff in the outpatient clinics, in the operating rooms, at the postoperative care unit, and at the wards. We also want to thank the Good Clinical Practice units at Copenhagen University Hospital and Odense University Hospital for their excellent cooperation—especially Birgitte Grøn, and Henriette Kunoy Bendixen. Lastly, we wish to offer our appreciation to all our participants for giving us the opportunity to implement our trial. The Good Clinical Practice units were compensated for monitoring the trial according to Danish legislation. No individuals received personal compensation.

Funding Information:
The trial was independently funded by the Novo Nordisk Foundation and Næstved-Slagelse-Ringsted Hospital's Research Fund. The Steering Committee would like to express our sincere gratitude to our collaborators. This trial could not have been conducted without major contributions from our research staff and the clinical staff in the outpatient clinics, in the operating rooms, at the postoperative care unit, and at the wards. We also want to thank the Good Clinical Practice units at Copenhagen University Hospital and Odense University Hospital for their excellent cooperation—especially Birgitte Grøn, and Henriette Kunoy Bendixen. Lastly, we wish to offer our appreciation to all our participants for giving us the opportunity to implement our trial. The Good Clinical Practice units were compensated for monitoring the trial according to Danish legislation. No individuals received personal compensation.

Publisher Copyright:
© 2024 Elsevier Ltd

ID: 386491452